ImmunoPrecise Antibodies Ltd.

NASDAQ

Market Cap.

48.51M

Avg. Volume

1.85M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. News

ImmunoPrecise Antibodies Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
ipatherapeutics.com

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

ImmunoPrecise Antibodies Ltd. Earnings & Revenue

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

ImmunoPrecise Antibodies Ltd. Financials

Table Compare

Compare IPA metrics with:

   

Earnings & Growth

IPA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

IPA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

IPA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

IPA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

ImmunoPrecise Antibodies Ltd. Income

ImmunoPrecise Antibodies Ltd. Balance Sheet

ImmunoPrecise Antibodies Ltd. Cash Flow

ImmunoPrecise Antibodies Ltd. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

ImmunoPrecise Antibodies Ltd. Executives

NameRole
Dr. Jennifer Lynne Bath Ph.D.Chief Executive Officer, President & Non-Independent Director
Dr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, Oss
Ms. Kari GraberVice President of Commercial Services
Mr. Joseph SchefflerInterim Chief Financial Officer
NameRoleGenderDate of BirthPay
Dr. Jennifer Lynne Bath Ph.D.Chief Executive Officer, President & Non-Independent Director720.25K
Dr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, Oss198.4K
Ms. Kari GraberVice President of Commercial ServicesFemale196.01K
Mr. Joseph SchefflerInterim Chief Financial OfficerMale

--

ImmunoPrecise Antibodies Ltd. Insider Trades

Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionDisposed
TypeJ-Other
Shares10000
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionDisposed
TypeJ-Other
Shares1
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares1
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares10412
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares861826
DateNameRoleTransactionTypeShares
12 DecAisling Capital II LP10 percent ownerDisposedJ-Other10000
12 DecAisling Capital II LP10 percent ownerDisposedJ-Other1
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other1
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other10412
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other861826

Discover More

Streamlined Academy

ImmunoPrecise Antibodies Ltd.

NASDAQ

Market Cap.

48.51M

Avg. Volume

1.85M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

ImmunoPrecise Antibodies Ltd. News

ImmunoPrecise Antibodies Ltd. Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

ImmunoPrecise Antibodies Ltd. Earnings & Revenue

ImmunoPrecise Antibodies Ltd. Income

ImmunoPrecise Antibodies Ltd. Balance Sheet

ImmunoPrecise Antibodies Ltd. Cash Flow

ImmunoPrecise Antibodies Ltd. Financials Over Time

ImmunoPrecise Antibodies Ltd. Executives

NameRole
Dr. Jennifer Lynne Bath Ph.D.Chief Executive Officer, President & Non-Independent Director
Dr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, Oss
Ms. Kari GraberVice President of Commercial Services
Mr. Joseph SchefflerInterim Chief Financial Officer
NameRoleGenderDate of BirthPay
Dr. Jennifer Lynne Bath Ph.D.Chief Executive Officer, President & Non-Independent Director720.25K
Dr. Ilse RoodinkChief Scientific Officer & Interim General Manager of IPA Europe, Oss198.4K
Ms. Kari GraberVice President of Commercial ServicesFemale196.01K
Mr. Joseph SchefflerInterim Chief Financial OfficerMale

--

ImmunoPrecise Antibodies Ltd. Insider Trades

Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionDisposed
TypeJ-Other
Shares10000
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionDisposed
TypeJ-Other
Shares1
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares1
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares10412
Date12 Dec
NameAisling Capital II LP
Role10 percent owner
TransactionAcquired
TypeJ-Other
Shares861826
DateNameRoleTransactionTypeShares
12 DecAisling Capital II LP10 percent ownerDisposedJ-Other10000
12 DecAisling Capital II LP10 percent ownerDisposedJ-Other1
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other1
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other10412
12 DecAisling Capital II LP10 percent ownerAcquiredJ-Other861826

Streamlined Academy

Website screenshot
HealthcareBiotechnology
ipatherapeutics.com

About ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about ImmunoPrecise Antibodies Ltd.

What’s This Company Really Worth? Find Out Instantly.

Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.

ImmunoPrecise Antibodies Ltd. Financials

Table Compare

Compare IPA metrics with:

   

Earnings & Growth

IPA

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

IPA

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

IPA

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

IPA

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Sell
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioSell
Price/Earnings RatioStrong Sell
Price/Book RatioBuy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

The Secret to Analyzing Winning Stocks (Step-by-Step Examples Inside)